



Biotech Sector Survey: From Investment Confidence to Strategic Collaborations


In the rapidly evolving landscape, ICON's recently published biotech sector survey provides a roadmap through the intricacies of investment confidence, funding dynamics, and the pivotal role of strategic collaborations. The survey, conducted on ICON's behalf by Citeline, included 133 respondents, predominantly located in Europe and North America, from small pharmaceutical and biotech companies, mid-size pharmaceutical and biotech companies, to large biotech or venture capital organisations.

A compelling narrative unfolds as we dissect the survey results, revealing the industry's resilience and determination despite funding challenges. We explore the imperative of partnerships, delving into their role in funding strategies, and the increasing trend of pharma collaborations, even at the preclinical stage.

Key Survey Findings: Stats and Implications

R&D Spending Expectations

The heartbeat of the biotech innovation lies in its Research and Development (R&D) endeavours, and the survey paints a vivid picture of the sector's commitment to pushing the boundaries despite financial headwinds. 60% of survey respondents expect to increase their R&D spending over the next one to two years, a testament to the resilience that permeates the industry. This statistic is a powerful indicator of the industry's faith in the transformative potential of its research initiatives and the impact these endeavours can have on shaping the future of healthcare.



Despite the funding challenges that have become an intrinsic part of the biotech landscape, the overwhelming majority expressing an intent to boost R&D spending sends a powerful signal. It signifies a collective determination to forge ahead with novel research, undeterred by the financial uncertainties. This optimistic outlook not only underscores the resilience of biotech professionals but also speaks to a broader narrative of belief in the value and impact of the biotech innovation on global health.


These statistics symbolise a commitment to progress and a belief in the industry's ability to overcome obstacles. The biotech sector is not merely weathering the storm; it is actively

charting a course toward a future where innovative solutions can address some of the most pressing challenges in healthcare. As the industry braces for an uptick in R&D spending, it positions itself ready and able to unlock new frontiers in science and medicine.

Challenges in the Funding Landscape

In the complex interplay between innovation and financial viability, the survey unearths critical insights into the challenges embedded within the biotech funding landscape. A significant 47% of respondents identify the rising cost of capital as a substantial influencer. This finding underscores the industry's acute awareness of its financial pressures, with the cost of capital emerging as a pivotal factor shaping future operations. As biotechs navigate this upward trajectory in capital costs, strategic financial planning becomes paramount to sustaining momentum in drug development.

Furthermore, the survey reveals that 35% of respondents consider cost management a barrier to innovation. This finding adds a nuanced layer to the funding landscape, highlighting the delicate balance between financial prudence and fostering innovation. The industry's drive to innovate and bring transformative therapies to market is apparent. Yet, the challenges posed by cost management warrant carefully calibrating financial strategies to ensure sustained creativity and progress.



The implication of these findings is significant – the industry is at a crossroads where the imperative to innovate collides with the realities of financial constraints. Biotechs must navigate a delicate dance, strategically allocating resources to foster innovation while managing costs effectively. This challenge underscores the importance of creative financial models, strategic partnerships, and efficient operational practices to ensure that the flame of innovation continues to burn brightly. In essence, these survey findings highlight the financial tightrope biotech companies walk, emphasising the critical need for thoughtful financial management in pursuing groundbreaking advancements.

Investment Confidence and Product Success

In an operating environment where financial milestones intersect with the promise of product success, the survey findings point to a strong level of confidence within the





biotech industry. An overwhelming 93% of respondents express confidence in meeting their investment milestones, showcasing a robust belief in the industry's ability to secure the necessary financial backing for their endeavours. This high level of confidence signals optimism and a tangible assurance that the biotech sector can navigate the intricate landscape of investment despite the challenges posed by funding difficulties.


Moreover, an impressive 87% of respondents express confidence in the success of their products. Despite the complexities of clinical trials, financial uncertainties, and the evolving healthcare landscape, biotech companies are resolute in their conviction that their products will meet and exceed expectations.

Clinical Trials Landscape

32% of respondents cited clinical trials as the greatest challenge for their organisation, with 51% identifying phase 3 as the most challenging period. Clinical trials topped the list of challenges, beating securing funding, which was cited as the top problem by just 14% of respondents, despite the current financing situation, emphasising the complexity and intricacies of this pivotal stage.



When asked about the clinical trial challenges they face, respondents said clinical trials are extremely costly, require significant expertise and coordination, are the most time-consuming element, and that candidates willing to volunteer for clinical studies are hard to find. Furthermore, they also cited difficulties due to differing laws in different countries.



Partnering

The prominence of partnerships emerges as a strategic response to these challenges. A substantial 48% of respondents reveal that they are actively partnering with large pharmaceutical firms, signalling a recognition of the collaborative power established industry players bring. This strategic alignment with large pharma firms injects financial stability and provides access to invaluable expertise, resources, and an established infrastructure, potentially streamlining the clinical trial process.

The strategic role of partnerships in clinical trials is indispensable. In an environment where challenges are acknowledged, partnerships with large pharma firms and specialised CROs become tactical manoeuvres and strategic imperatives. These collaborations stand as a testament to the industry's recognition that the complexities of clinical trials demand a collaborative approach. They are committed to leveraging shared expertise, resources, and capabilities, thereby enhancing the efficiency, quality, and, ultimately, the success of clinical development endeavours. In essence, the clinical trials landscape outlined by the survey findings underscores the pivotal role of partnerships in navigating the intricate journey from research to regulatory approval.

Additionally, 41% of respondents express a preference for medium to large CROs when it comes to clinical development. This preference underscores the industry's reliance on specialised service providers, emphasising the value of working with CROs with a global presence and comprehensive service offerings. It also suggests that strategic collaborations with CROs play a crucial role in managing the intricacies of clinical trials, leveraging their expertise to optimise trial design, patient recruitment, and data management.



Looking Forward

When examining the findings of ICON's biotech sector survey, a comprehensive narrative emerges, painting a vivid portrait of an industry that survives and adapts amidst funding challenges. From R&D spending expectations to navigating the intricacies of the funding landscape and clinical trials, a resilient spirit permeates the biotech sector. Despite financial headwinds, the survey illuminates an industry-wide commitment to advancing innovation, as evidenced by a resounding 60% of respondents who anticipated increases in R&D spending.

The challenges embedded in the funding landscape, particularly the rising cost of capital and the delicate balance required for cost management, underscore the financial tightrope biotechs navigate. Yet, these challenges are not insurmountable. The industry acknowledges the imperative to innovate and is compelled to allocate resources, fostering creativity while managing costs effectively and strategically. The survey findings point to this financial balancing act, emphasising the critical need for thoughtful financial management to propel groundbreaking advancements.

Strategic partnerships emerge as a linchpin in overcoming challenges in the clinical trial landscape. A substantial 48% actively partner with large pharmaceutical firms, recognising the collaborative power they bring. Furthermore, 41% prefer medium-large CROs for clinical development, highlighting the industry's reliance on specialised service providers. These partnerships go beyond tactical manoeuvres; they are strategic

imperatives, reflecting an industry-wide commitment to collaborative approaches that enhance efficiency, quality, and the ultimate success of clinical development.

The survey outlines the challenges biotech organisations face and paints a portrait of an industry that is adapting to address them. The transformative potential of strategic partnerships, the unwavering confidence in innovation, and the commitment to navigating financial complexities can support biotech companies in their important work of driving innovative and scientific advancements of much needed medicines.



Dr. Chris Smyth

Dr. Chris Smyth is President of ICON Biotech. Dr. Smyth has 30 years' operational and therapeutic experience, most notably in biotech, MedTech and oncology. Prior to ICON, he spent 10 years in IQVIA Biotech, where he held EVP Oncology and Chief Operating Officer roles before assuming global leadership as President of the division. Dr. Smyth also previously led global clinical operations for 8 years at an oncology biotech company, Antisoma. Dr. Smyth holds a Bachelor of Science degree in Biochemistry from the University of Kent at Canterbury, a PhD in Reproductive Biology from the University of Edinburgh Medical School, and an MBA from Henley Management College.